Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Dimerix Limited ( (AU:DXB) ) has provided an announcement.
Dimerix Limited has made significant progress in the 2024-25 financial year by advancing its lead program, DMX-200, through the Phase 3 ACTION3 clinical trial for focal segmental glomerulosclerosis (FSGS), a condition with no approved therapies. The company has nearly completed patient recruitment and has entered into four commercial licensing agreements valued at up to $1.4 billion, which provide non-dilutive capital and de-risk development. These efforts position Dimerix for potential market approval and significant commercial opportunities, particularly in high-need markets, while also strengthening its operational and scientific credibility.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix is a biopharmaceutical company focused on developing innovative therapies for areas with unmet medical needs. The company is headquartered in Fitzroy, Victoria, Australia.
Average Trading Volume: 1,212,857
Technical Sentiment Signal: Buy
Current Market Cap: A$288.2M
See more insights into DXB stock on TipRanks’ Stock Analysis page.